Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type

Annarita Conconi, Giovanni Martinelli, Catherine Thiéblemont, Andrés J M Ferreri, Liliana Devizzi, Fedro Peccatori, Maurilio Ponzoni, Ennio Pedrinis, Stefania Dell'Oro, Giancarlo Pruneri, Virginio Filipazzi, Pierre Yves Dietrich, Alessandro M. Gianni, Bertrand Coiffier, Franco Cavalli, Emanuele Zucca

Research output: Contribution to journalArticle

305 Citations (Scopus)

Abstract

The clinical activity of rituximab has been evaluated in a phase 2 study in both untreated and relapsed mucosa-associated lymphoid tissue (MALT) lymphomas. Treatment consisted of 4 standard (375 mg/m2) weekly doses. Thirty-five patients were enrolled, and 34 completed the treatment program. The primary lymphoma location was stomach in 15 patients, and extragastric in 20. Eleven patients had previously been treated with chemotherapy. At study entry 12 patients had Ann Arbor stage IE, 3 had stage IIE, and 20 had stage IV disease. The overall response rate was 73% (95% confidence interval, 56%-87%), with 15 complete responses and 10 partial responses, and the response rate was significantly higher in the chemotherapy-naive patients, who had an 87% response rate compared with 45% of the previously treated patients (P = .03). The median response duration was 10. 5 months. At a median follow-up of 15 months, 9 patients (26%) relapsed. The median time to treatment failure was 14.2 months in the whole series, but it was significantly longer (22 versus 12 months) in the chemotherapy-naive patients compared with those who had prior chemotherapy (P = .001). Most adverse events were of mild to moderate severity with no grade 4 toxicity. This study indicates that rituximab is safe with significant activity in MALT lymphomas.

Original languageEnglish
Pages (from-to)2741-2745
Number of pages5
JournalBlood
Volume102
Issue number8
DOIs
Publication statusPublished - Oct 15 2003

Fingerprint

Marginal Zone B-Cell Lymphoma
Chemotherapy
Cells
Tissue
Drug Therapy
Toxicity
Rituximab
Mucous Membrane
Treatment Failure
Lymphoma
Stomach
Confidence Intervals
Therapeutics

ASJC Scopus subject areas

  • Hematology

Cite this

Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. / Conconi, Annarita; Martinelli, Giovanni; Thiéblemont, Catherine; Ferreri, Andrés J M; Devizzi, Liliana; Peccatori, Fedro; Ponzoni, Maurilio; Pedrinis, Ennio; Dell'Oro, Stefania; Pruneri, Giancarlo; Filipazzi, Virginio; Dietrich, Pierre Yves; Gianni, Alessandro M.; Coiffier, Bertrand; Cavalli, Franco; Zucca, Emanuele.

In: Blood, Vol. 102, No. 8, 15.10.2003, p. 2741-2745.

Research output: Contribution to journalArticle

Conconi, A, Martinelli, G, Thiéblemont, C, Ferreri, AJM, Devizzi, L, Peccatori, F, Ponzoni, M, Pedrinis, E, Dell'Oro, S, Pruneri, G, Filipazzi, V, Dietrich, PY, Gianni, AM, Coiffier, B, Cavalli, F & Zucca, E 2003, 'Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type', Blood, vol. 102, no. 8, pp. 2741-2745. https://doi.org/10.1182/blood-2002-11-3496
Conconi, Annarita ; Martinelli, Giovanni ; Thiéblemont, Catherine ; Ferreri, Andrés J M ; Devizzi, Liliana ; Peccatori, Fedro ; Ponzoni, Maurilio ; Pedrinis, Ennio ; Dell'Oro, Stefania ; Pruneri, Giancarlo ; Filipazzi, Virginio ; Dietrich, Pierre Yves ; Gianni, Alessandro M. ; Coiffier, Bertrand ; Cavalli, Franco ; Zucca, Emanuele. / Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. In: Blood. 2003 ; Vol. 102, No. 8. pp. 2741-2745.
@article{84b46be1df35419e81273dd8129ecd96,
title = "Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type",
abstract = "The clinical activity of rituximab has been evaluated in a phase 2 study in both untreated and relapsed mucosa-associated lymphoid tissue (MALT) lymphomas. Treatment consisted of 4 standard (375 mg/m2) weekly doses. Thirty-five patients were enrolled, and 34 completed the treatment program. The primary lymphoma location was stomach in 15 patients, and extragastric in 20. Eleven patients had previously been treated with chemotherapy. At study entry 12 patients had Ann Arbor stage IE, 3 had stage IIE, and 20 had stage IV disease. The overall response rate was 73{\%} (95{\%} confidence interval, 56{\%}-87{\%}), with 15 complete responses and 10 partial responses, and the response rate was significantly higher in the chemotherapy-naive patients, who had an 87{\%} response rate compared with 45{\%} of the previously treated patients (P = .03). The median response duration was 10. 5 months. At a median follow-up of 15 months, 9 patients (26{\%}) relapsed. The median time to treatment failure was 14.2 months in the whole series, but it was significantly longer (22 versus 12 months) in the chemotherapy-naive patients compared with those who had prior chemotherapy (P = .001). Most adverse events were of mild to moderate severity with no grade 4 toxicity. This study indicates that rituximab is safe with significant activity in MALT lymphomas.",
author = "Annarita Conconi and Giovanni Martinelli and Catherine Thi{\'e}blemont and Ferreri, {Andr{\'e}s J M} and Liliana Devizzi and Fedro Peccatori and Maurilio Ponzoni and Ennio Pedrinis and Stefania Dell'Oro and Giancarlo Pruneri and Virginio Filipazzi and Dietrich, {Pierre Yves} and Gianni, {Alessandro M.} and Bertrand Coiffier and Franco Cavalli and Emanuele Zucca",
year = "2003",
month = "10",
day = "15",
doi = "10.1182/blood-2002-11-3496",
language = "English",
volume = "102",
pages = "2741--2745",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "8",

}

TY - JOUR

T1 - Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type

AU - Conconi, Annarita

AU - Martinelli, Giovanni

AU - Thiéblemont, Catherine

AU - Ferreri, Andrés J M

AU - Devizzi, Liliana

AU - Peccatori, Fedro

AU - Ponzoni, Maurilio

AU - Pedrinis, Ennio

AU - Dell'Oro, Stefania

AU - Pruneri, Giancarlo

AU - Filipazzi, Virginio

AU - Dietrich, Pierre Yves

AU - Gianni, Alessandro M.

AU - Coiffier, Bertrand

AU - Cavalli, Franco

AU - Zucca, Emanuele

PY - 2003/10/15

Y1 - 2003/10/15

N2 - The clinical activity of rituximab has been evaluated in a phase 2 study in both untreated and relapsed mucosa-associated lymphoid tissue (MALT) lymphomas. Treatment consisted of 4 standard (375 mg/m2) weekly doses. Thirty-five patients were enrolled, and 34 completed the treatment program. The primary lymphoma location was stomach in 15 patients, and extragastric in 20. Eleven patients had previously been treated with chemotherapy. At study entry 12 patients had Ann Arbor stage IE, 3 had stage IIE, and 20 had stage IV disease. The overall response rate was 73% (95% confidence interval, 56%-87%), with 15 complete responses and 10 partial responses, and the response rate was significantly higher in the chemotherapy-naive patients, who had an 87% response rate compared with 45% of the previously treated patients (P = .03). The median response duration was 10. 5 months. At a median follow-up of 15 months, 9 patients (26%) relapsed. The median time to treatment failure was 14.2 months in the whole series, but it was significantly longer (22 versus 12 months) in the chemotherapy-naive patients compared with those who had prior chemotherapy (P = .001). Most adverse events were of mild to moderate severity with no grade 4 toxicity. This study indicates that rituximab is safe with significant activity in MALT lymphomas.

AB - The clinical activity of rituximab has been evaluated in a phase 2 study in both untreated and relapsed mucosa-associated lymphoid tissue (MALT) lymphomas. Treatment consisted of 4 standard (375 mg/m2) weekly doses. Thirty-five patients were enrolled, and 34 completed the treatment program. The primary lymphoma location was stomach in 15 patients, and extragastric in 20. Eleven patients had previously been treated with chemotherapy. At study entry 12 patients had Ann Arbor stage IE, 3 had stage IIE, and 20 had stage IV disease. The overall response rate was 73% (95% confidence interval, 56%-87%), with 15 complete responses and 10 partial responses, and the response rate was significantly higher in the chemotherapy-naive patients, who had an 87% response rate compared with 45% of the previously treated patients (P = .03). The median response duration was 10. 5 months. At a median follow-up of 15 months, 9 patients (26%) relapsed. The median time to treatment failure was 14.2 months in the whole series, but it was significantly longer (22 versus 12 months) in the chemotherapy-naive patients compared with those who had prior chemotherapy (P = .001). Most adverse events were of mild to moderate severity with no grade 4 toxicity. This study indicates that rituximab is safe with significant activity in MALT lymphomas.

UR - http://www.scopus.com/inward/record.url?scp=0141923917&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141923917&partnerID=8YFLogxK

U2 - 10.1182/blood-2002-11-3496

DO - 10.1182/blood-2002-11-3496

M3 - Article

C2 - 12842999

AN - SCOPUS:0141923917

VL - 102

SP - 2741

EP - 2745

JO - Blood

JF - Blood

SN - 0006-4971

IS - 8

ER -